메뉴 건너뛰기




Volumn 15, Issue 12, 2010, Pages 1359-1369

Impact of safety concerns and regulatory changes on the usage of erythropoiesis-stimulating agents and RBC transfusions

Author keywords

Anemia; Erythropoiesis stimulating agents; RBC transfusions; Regulatory restrictions

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; HEMOGLOBIN;

EID: 78650990316     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0293     Document Type: Article
Times cited : (18)

References (39)
  • 1
    • 5344263788 scopus 로고    scopus 로고
    • The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients
    • Ludwig H, Van Belle S, Barrett-Lee P et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-2306.
    • (2004) Eur J Cancer , vol.40 , pp. 2293-2306
    • Ludwig, H.1    van Belle, S.2    Barrett-Lee, P.3
  • 2
    • 0033530262 scopus 로고    scopus 로고
    • Chemotherapy-induced anemia in adults: Incidence and treatment
    • Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
    • (1999) J Natl Cancer Inst , vol.91 , pp. 1616-1634
    • Groopman, J.E.1    Itri, L.M.2
  • 3
    • 0002929285 scopus 로고
    • Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy
    • Henry DH, Brooks BJ Jr, Case DC Jr et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am 1995;1:252-260.
    • (1995) Cancer J Sci Am , vol.1 , pp. 252-260
    • Henry, D.H.1    Brooks Jr., B.J.2    Case Jr., D.C.3
  • 4
    • 0037151364 scopus 로고    scopus 로고
    • Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy
    • Vansteenkiste J, Pirker R, Massuti B et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220.
    • (2002) J Natl Cancer Inst , vol.94 , pp. 1211-1220
    • Vansteenkiste, J.1    Pirker, R.2    Massuti, B.3
  • 5
    • 0031044609 scopus 로고    scopus 로고
    • Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
    • Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15:1218-1234.
    • (1997) J Clin Oncol , vol.15 , pp. 1218-1234
    • Glaspy, J.1    Bukowski, R.2    Steinberg, D.3
  • 6
    • 0031785826 scopus 로고    scopus 로고
    • Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group
    • Demetri GD, Kris M, Wade J et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-3425.
    • (1998) J Clin Oncol , vol.16 , pp. 3412-3425
    • Demetri, G.D.1    Kris, M.2    Wade, J.3
  • 7
    • 0035367087 scopus 로고    scopus 로고
    • Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebocontrolled trial
    • Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebocontrolled trial. J Clin Oncol 2001;19:2865-2874.
    • (2001) J Clin Oncol , vol.19 , pp. 2865-2874
    • Littlewood, T.J.1    Bajetta, E.2    Nortier, J.W.3
  • 8
    • 33744822764 scopus 로고    scopus 로고
    • Randomized comparison of every-2 -week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: The 200030125 Study Group Trial
    • Glaspy J, Vadhan-Raj S, Patel R et al. Randomized comparison of every-2 -week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: The 200030125 Study Group Trial. J Clin Oncol 2006;24:2290-2297.
    • (2006) J Clin Oncol , vol.24 , pp. 2290-2297
    • Glaspy, J.1    Vadhan-Raj, S.2    Patel, R.3
  • 9
    • 1542324739 scopus 로고    scopus 로고
    • Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks
    • Vadhan-Raj S, Mirtsching B, Charu V et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol 2003;1:131-138.
    • (2003) J Support Oncol , vol.1 , pp. 131-138
    • Vadhan-Raj, S.1    Mirtsching, B.2    Charu, V.3
  • 10
    • 0035366382 scopus 로고    scopus 로고
    • Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
    • Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
    • (2001) J Clin Oncol , vol.19 , pp. 2875-2882
    • Gabrilove, J.L.1    Cleeland, C.S.2    Livingston, R.B.3
  • 11
    • 0042889128 scopus 로고    scopus 로고
    • Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy
    • Shasta D, George MJ, Harrison LB. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003;98:1072-1079.
    • (2003) Cancer , vol.98 , pp. 1072-1079
    • Shasta, D.1    George, M.J.2    Harrison, L.B.3
  • 12
    • 0142186283 scopus 로고    scopus 로고
    • Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomized, double-blind, placebo-controlled trial
    • Henke M, Laszig R, Rübe C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomized, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
    • (2003) Lancet , vol.362 , pp. 1255-1260
    • Henke, M.1    Laszig, R.2    Rübe, C.3
  • 13
    • 24944454286 scopus 로고    scopus 로고
    • Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study
    • Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005;23:5960-5972.
    • (2005) J Clin Oncol , vol.23 , pp. 5960-5972
    • Leyland-Jones, B.1    Semiglazov, V.2    Pawlicki, M.3
  • 14
    • 34047221511 scopus 로고    scopus 로고
    • Randomized, double-blind, placebocontrolled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia
    • Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebocontrolled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027-1032.
    • (2007) J Clin Oncol , vol.25 , pp. 1027-1032
    • Wright, J.R.1    Ung, Y.C.2    Julian, J.A.3
  • 15
    • 38649128164 scopus 로고    scopus 로고
    • Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dl with erythropoietin vs above 10.0 g/dl without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer
    • Thomas G, Ali S, Hoebers FJ et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dl with erythropoietin vs above 10.0 g/dl without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008;108: 317-325.
    • (2008) Gynecol Oncol , vol.108 , pp. 317-325
    • Thomas, G.1    Ali, S.2    Hoebers, F.J.3
  • 16
    • 34250349918 scopus 로고    scopus 로고
    • Danish researchers post long-awaited Aranesp results-ever so discreetly
    • Goldberg P. Danish researchers post long-awaited Aranesp results-ever so discreetly. Cancer Lett 2007;33:1-6.
    • (2007) Cancer Lett , vol.33 , pp. 1-6
    • Goldberg, P.1
  • 17
    • 40549088086 scopus 로고    scopus 로고
    • Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): The Danish Head and Neck Cancer Group DAHANCA 10 rand [abstract]
    • Overgaard J, Hoff C, Sand Hansen H et al. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): The Danish Head and Neck Cancer Group DAHANCA 10 rand [abstract]. Eur J Cancer 2007;5:7.
    • (2007) Eur J Cancer , vol.5 , pp. 7
    • Overgaard, J.1    Hoff, C.2    Sand, H.H.3
  • 18
    • 28444469283 scopus 로고    scopus 로고
    • Randomized, doubleblind, placebo-controlled trial of epoetin alfa (Procrit) in patients with rectal and gastric cancer undergoing chemo-radiotherapy (CT/RT) followed by surgery: Early termination of the trial due to increased incidence of thrombo-embolic events (TEE)
    • Vadhan-Raj S, Crane C, Bueso-Ramos CE et al. Randomized, doubleblind, placebo-controlled trial of epoetin alfa (Procrit) in patients with rectal and gastric cancer undergoing chemo-radiotherapy (CT/RT) followed by surgery: Early termination of the trial due to increased incidence of thrombo-embolic events (TEE). Blood 104:797a.
    • Blood , vol.104
    • Vadhan-Raj, S.1    Crane, C.2    Bueso-Ramos, C.E.3
  • 19
    • 0041627742 scopus 로고    scopus 로고
    • Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies:A randomized, double-blind, placebo-controlled study
    • Hedenus M, Adriansson M, San Miguel J et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies:A randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122:394-403.
    • (2003) Br J Haematol , vol.122 , pp. 394-403
    • Hedenus, M.1    Adriansson, M.2    San, M.J.3
  • 20
    • 41949140285 scopus 로고    scopus 로고
    • Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled study
    • Smith RE, Aapro MS, Ludwig H et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040-1050.
    • (2008) J Clin Oncol , vol.26 , pp. 1040-1050
    • Smith, R.E.1    Aapro, M.S.2    Ludwig, H.3
  • 21
    • 40349103260 scopus 로고    scopus 로고
    • Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia
    • Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299:914-924.
    • (2008) JAMA , vol.299 , pp. 914-924
    • Bennett, C.L.1    Silver, S.M.2    Djulbegovic, B.3
  • 22
    • 50349088773 scopus 로고    scopus 로고
    • Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer
    • Juneja V, Keegan P, Gootenberg JE et al. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer. Clin Cancer Res 2008;14:3242-3247.
    • (2008) Clin Cancer Res , vol.14 , pp. 3242-3247
    • Juneja, V.1    Keegan, P.2    Gootenberg, J.E.3
  • 23
    • 77951700065 scopus 로고    scopus 로고
    • U.S. Food and Drug Administration, March 2007 label. Available at, accessed March 11, 2009
    • U.S. Food and Drug Administration. Drugs at FDA: Pocrit and Epogen label. March 2007 label. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103234s5122lbl.pdf, accessed March 11, 2009.
    • Drugs at FDA: Pocrit and Epogen Label
  • 24
    • 38049083499 scopus 로고    scopus 로고
    • Centers for Medicare & Medicaid Services, Washington, DC: Department of Health & Human Services, Available at, accessed November 17, 2010
    • Centers for Medicare & Medicaid Services. Decision Memo for Erythropoiesis Stimulating Agents (ESAs) for Non-Renal Disease Indications (CAG-00383N). Washington, DC: Department of Health & Human Services, 2007. Available at https://www.cms.gov/mcd/viewdecisionmemo.asp?id=203, accessed November 17, 2010.
    • (2007) Decision Memo for Erythropoiesis Stimulating Agents (ESAs) for Non-Renal Disease Indications (CAG-00383N)
  • 25
    • 78650983148 scopus 로고    scopus 로고
    • U.S. Food and Drug Administration, November, label. Available at, accessed March 11, 2009
    • U.S. Food and Drug Administration. Drugs at FDA: Procrit and Epogen Label. November 2007 label. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103234s5158lbl.pdf, accessed March 11, 2009.
    • (2007) Drugs at FDA: Procrit and Epogen Label
  • 26
    • 77951700065 scopus 로고    scopus 로고
    • U.S. Food and Drug Administration, November 2007 label. Available at, accessed March 11, 2009
    • U.S. Food and Drug Administration. Drugs at FDA: Aranesp® (Darbepoetin Alfa) For Injection. November 2007 label. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103951s5164lbl.pdf, accessed March 11, 2009.
    • Drugs at FDA: Aranesp® (Darbepoetin Alfa) for Injection
  • 27
    • 77957714130 scopus 로고    scopus 로고
    • Continued regulatory actions affecting the use of erythropoiesis-stimulating Agents
    • Hagerty K. Continued regulatory actions affecting the use of erythropoiesis-stimulating Agents. J Oncol Pract 2008;4:267-270.
    • (2008) J Oncol Pract , vol.4 , pp. 267-270
    • Hagerty, K.1
  • 29
    • 78549286047 scopus 로고    scopus 로고
    • American Society of Hematology/ American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer
    • Rizzo JD, Brouwers M, Hurley P et al. American Society of Hematology/ American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood; 2010;116:4045-4059.
    • (2010) Blood , vol.116 , pp. 4045-4059
    • Rizzo, J.D.1    Brouwers, M.2    Hurley, P.3
  • 31
    • 65349104834 scopus 로고    scopus 로고
    • Impact of limiting erythropoiesisstimulating agent use for chemotherapy induced anemia on the United States blood supply margin
    • Vekeman F, Bookhart BK, Duh MS et al. Impact of limiting erythropoiesisstimulating agent use for chemotherapy induced anemia on the United States blood supply margin. Transfusion 2009;49:895-902.
    • (2009) Transfusion , vol.49 , pp. 895-902
    • Vekeman, F.1    Bookhart, B.K.2    Duh, M.S.3
  • 32
    • 39049138428 scopus 로고    scopus 로고
    • Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies ((DOSE): A registry for characterizing anaemia management and outcomes in oncology patients
    • Larholt K, Pashos CL, Wang Q et al. Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies ((DOSE): A registry for characterizing anaemia management and outcomes in oncology patients. Clin Drug Investig 2008;28:159-167.
    • (2008) Clin Drug Investig , vol.28 , pp. 159-167
    • Larholt, K.1    Pashos, C.L.2    Wang, Q.3
  • 33
    • 78650994365 scopus 로고    scopus 로고
    • Changes in RBC supportive medications and transfusions in cancer patients undergoing chemotherapy before and after FDA and Medicare actions in 2007 [abstract 20595]
    • Nailm A, Glaspy J. Changes in RBC supportive medications and transfusions in cancer patients undergoing chemotherapy before and after FDA and Medicare actions in 2007 [abstract 20595]. J Clin Oncol 2008;26(15 suppl):732s.
    • (2008) J Clin Oncol , vol.26 , Issue.15 SUPPL
    • Nailm, A.1    Glaspy, J.2
  • 35
    • 31444447968 scopus 로고    scopus 로고
    • Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: An integrated analysis of the Canadian experience
    • Quirt I, Kovacs M, Couture F et al. Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: An integrated analysis of the Canadian experience. The Oncologist 2006;11:73-82.
    • (2006) The Oncologist , vol.11 , pp. 73-82
    • Quirt, I.1    Kovacs, M.2    Couture, F.3
  • 36
    • 54049148231 scopus 로고    scopus 로고
    • Treatment options for anemia, taking risks into consideration: Erythropoiesis-stimulating agents versus transfusions
    • Spano JP, Khayat D. Treatment options for anemia, taking risks into consideration: Erythropoiesis-stimulating agents versus transfusions. The Oncologist 2008;13(suppl 3):27-32.
    • (2008) The Oncologist , vol.13 , Issue.SUPPL. 3 , pp. 27-32
    • Spano, J.P.1    Khayat, D.2
  • 37
    • 12844275064 scopus 로고    scopus 로고
    • Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management
    • Couture F, Turner AR, Melosky B et al. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management. The Oncologist 2005;10: 63-71.
    • (2005) The Oncologist , vol.10 , pp. 63-71
    • Couture, F.1    Turner, A.R.2    Melosky, B.3
  • 38
    • 78650982185 scopus 로고    scopus 로고
    • Impact of safety concerns of erythropoiesis-stimulating agents (ESAs) and regulatory changes on the use of ESAs and red blood cell (RBC) transfusions at a comprehensive cancer center [abstract 1300]
    • Vadhan-Raj S, Hawkins V, Zhou X et al. Impact of safety concerns of erythropoiesis-stimulating agents (ESAs) and regulatory changes on the use of ESAs and red blood cell (RBC) transfusions at a comprehensive cancer center [abstract 1300]. Blood 2008;112:470.
    • (2008) Blood , vol.112 , pp. 470
    • Vadhan-Raj, S.1    Hawkins, V.2    Zhou, X.3
  • 39
    • 78650985531 scopus 로고    scopus 로고
    • The impact of randomized trial results and altered regulatory policies on ESA use, transfusions and thrombosis: A longitudinal analysis over a 3-year period of resource utilization data from a large comprehensive program [abstract 6611]
    • Shapira I, Raftopoulos H, Gralla RJ et al. The impact of randomized trial results and altered regulatory policies on ESA use, transfusions and thrombosis: A longitudinal analysis over a 3-year period of resource utilization data from a large comprehensive program [abstract 6611]. J Clin Oncol 2009;27(15 suppl):350s.
    • (2009) J Clin Oncol , vol.27 , Issue.15 SUPPL
    • Shapira, I.1    Raftopoulos, H.2    Gralla, R.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.